Location Directory

Clinical trials in Los Angeles, California

This page shows live ClinicalTrials.gov search results for Los Angeles, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:43 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

4634

Shown on this page

Current sort

Institutions in Los Angeles

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Kissimmee, Florida + 10 more

Conditions: Extrapulmonary Neuroendocrine Cancer (epNEC)
Interventions: Obrixtamig, Carboplatin, Etoposide, Ventana DLL3 RxDx assay; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • San Francisco, California + 17 more

Conditions: Congenital Cytomegaloviral (CMV) Disease
Interventions: CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy; Biological · Drug
Lead sponsor: New York Medical College; Other
Eligibility: 0 Days to 21 Days
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • St Louis, Missouri • Vallhala, New York + 1 more

Conditions: Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Interventions: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 16
States / cities: Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Interventions: INBRX-106, Pembrolizumab; Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 26
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 22 more

Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions: Nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more

Conditions: Ureteral Diseases
Interventions: Uriprene® Degradable Temporary Ureteral Stent; Device
Lead sponsor: Adva-Tec; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 1 more

Conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
Interventions: BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI); Drug
Lead sponsor: Bold Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Santa Monica, California • Tampa, Florida

Conditions: Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Quality-of-Life Assessment; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1026
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more

Conditions: Congenital Haemophilia
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Hartford, Connecticut + 19 more

Conditions: Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult Cancer Patients, CNS Tumor, Childhood, CNS Tumor, Adult, Brainstem Glioma, Diffuse Midline Glioma, DMG
Interventions: BCB-276; Biological
Lead sponsor: BrainChild Bio, Inc; Industry
Eligibility: 1 Year to 26 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Sickle Cell Disease
Interventions: Pociredir; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 8
States / cities: Little Rock, Arkansas • Los Angeles, California • Baton Rouge, Louisiana + 5 more

Clinical trials in Los Angeles, California

Filter and sort this location

Institutions in Los Angeles

Live official records

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

CMV CTLs in Neonates With CMV Infection

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Compassionate Use of Concizumab if You Have Haemophilia

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

Open-Label Extension Study to Pioneer Study 6058-SCD-101